In last trading session, Immunovant Inc (NASDAQ:IMVT) saw 1.43 million shares changing hands with its beta currently measuring 0.70. Company’s recent per share price level of $32.20 trading at -$0.89 or -2.69% at ring of the bell on the day assigns it a market valuation of $4.68B. That closing price of IMVT’s stock is at a discount of -41.55% from its 52-week high price of $45.58 and is indicating a premium of 56.37% from its 52-week low price of $14.05. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.47 million shares which gives us an average trading volume of 1.30 million if we extend that period to 3-months.
Immunovant Inc (NASDAQ:IMVT) trade information
Upright in the red during last session for losing -2.69%, in the last five days IMVT remained trading in the green while hitting it’s week-highest on Thursday, 03/21/24 when the stock touched $32.20 price level, adding 10.48% to its value on the day. Immunovant Inc’s shares saw a change of -23.57% in year-to-date performance and have moved 5.47% in past 5-day. Immunovant Inc (NASDAQ:IMVT) showed a performance of -10.53% in past 30-days. Number of shares sold short was 8.68 million shares which calculate 7.62 days to cover the short interests.
Immunovant Inc (IMVT) estimates and forecasts
Statistics highlight that Immunovant Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 51.53% of value to its shares in past 6 months, showing an annual growth rate of -4.68% while that of industry is 12.00. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 6.50% in the current quarter and calculating 21.10% increase in the next quarter.
In 2024, company’s earnings growth rate is likely to be around -4.20% while estimates for its earnings growth in next 5 years are of 3.69%.
IMVT Dividends
Immunovant Inc is more likely to be releasing its next quarterly report between May 13 and May 27 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Immunovant Inc (NASDAQ:IMVT)’s Major holders
Insiders are in possession of 55.50% of company’s total shares while institution are holding 47.57 percent of that, with stock having share float percentage of 106.91%. Investors also watch the number of corporate investors in a company very closely, which is 47.57% institutions for Immunovant Inc that are currently holding shares of the company. Vanguard Group Inc is the top institutional holder at IMVT for having 5.47 million shares of worth $103.74 million. And as of Jun 29, 2023, it was holding 4.19% of the company’s outstanding shares.
The second largest institutional holder is Deep Track Capital, Lp, which was holding about 5.42 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 4.15% of outstanding shares, having a total worth of $102.84 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2023, the former fund manager was holding 2.12 million shares of worth $48.15 million or 1.62% of the total outstanding shares. The later fund manager was in possession of 1.91 million shares on Aug 30, 2023, making its stake of worth around $43.4 million in the company or a holder of 1.46% of company’s stock.
